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BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma
(GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).
METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received
500mg of hydroxyurea twice a day. Imatinib was administered at 600mg per day for patients not on EIAEDs and at 500mg twice a
day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free
survival at 6 months (PFS-6), and overall survival (OS).
RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were
10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater
adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%).
CONCLUSION: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically
meaningful anti-tumour activity.
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There are currently few effective treatment options available for
adults with glioblastoma (GBM), the most common malignant
primary brain tumour. Median survival for newly diagnosed GBM
is approximately 15 months from diagnosis, after standard therapy
of temozolomide (TMZ) and radiotherapy and only 26% of
patients survive 2 years (Stupp et al, 2005). Although recent
studies with therapeutics targeting vascular endothelial growth
factor (VEGF) have shown encouraging results (Vredenburgh et al,
2007; Friedman et al, 2009), most salvage therapies after
progression have proven ineffective, with a median time to
progression of only 9 weeks, low response rates and life expectancy
of only a few months (Wong et al, 1999; Ballman et al, 2007;
Lamborn et al, 2008).
Imatinib mesylate (Glivec or Gleevec), a tyrosine kinase
inhibitor of platelet-derived growth factor receptors (PDGFRs)
a and b; c-KIT, the receptor for stem cell factor; c-Fms, the
receptor for macrophage-colony stimulating factor; Abl, and Arg
TK, is currently approved for several indications including
Philadelphia chromosome-positive (Phþ) chronic myelogenous
leukaemia, Phþ acute lymphoblastic leukaemia, KIT (CD 117)-
positive, unresectable or metastatic malignant gastrointestinal
stromal tumours, and four rare diseases (hypereosinophilic
syndrome, dermatofibrosarcoma protuberans, myelodysplastic/
myeloproliferative diseases, and systemic mastocytosis).
Several factors suggest that imatinib may be an active
therapeutic for malignant glioma. First, gliomas frequently over-
express PDGF and PDGFRs in an autocrine/paracrine manner
(Nister et al, 1988; Hermanson et al, 1992; Guha et al, 1995; Lokker
et al, 2002). Second, c-KIT is expressed by many GBM tumours
(Went et al, 2004; Joensuu et al, 2005). Third, imatinib inhibits the
growth of human GBM cell lines and prolongs survival of nude
mice with intracranial GBM cell implants (Kilic et al, 2000),
whereas expression of PDGFR and the chemokine CXCL12/SDF-1
(stromal cell-derived factor-1) predict imatinib sensitivity in vitro
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s(Hagerstrand et al, 2006). Finally, imatinib can sensitise human
GBM cells to ionising radiation (Russell et al, 2003; Holdhoff et al,
2005).
Preclinical evidence suggests that imatinib may enhance
chemosensitivity by several possible mechanisms, including
decreasing interstitial fluid pressure (Heuchel et al, 1999; Pietras
et al, 2001, 2002, 2003; Ostman, 2004), decreasing angiogenesis
(Bergers et al, 2003; Dudley et al, 2003; Hwang et al, 2003; Uehara
et al, 2003; Apte et al, 2004; Pietras and Hanahan, 2005), and by
affecting DNA repair mechanisms (Aloyz et al, 2004), stromal
chemokines (Ostman, 2004), and multidrug transporter activity
(Houghton et al, 2004; Ozvegy-Laczka et al, 2004). However, the
uptake and distribution of imatinib in the brain is limited by
P-gp/BCRP-mediated efflux (Dai et al, 2003), suggesting that
combination regimens with imatinib may be more effective than
imatinib monotherapy. Clinical studies evaluating imatinib as
monotherapy in relapsed GBM showed response rates ranging
from 3 to 6% and a progression-free survival at 6 months (PFS-6)
rate of 16% (Wen et al, 2006; Raymond et al, 2008).
Hydroxyurea (HU) has been used in multiagent regimens
against GBM, medulloblastoma, and metastatic brain tumours
(Levin and Prados, 1992; Geyer et al, 1994; Kyritsis et al, 1996;
Kaba et al, 1997; Prados et al, 1998). Hydroxyurea exerts a cell-
cycle-specific effect during early S-phase, through inhibition of
ribonucleotide reductase, thereby blocking DNA synthesis
(Kyritsis et al, 1996). Hydroxyurea exhibits rapid absorption from
the gastrointestinal tract after oral dosing and readily crosses the
blood–brain barrier. Independently conducted, single-institu-
tional clinical studies have noted anti-tumour activity among
patients with recurrent grade 3 (Desjardins et al, 2007) and 4
malignant glioma (Dresemann, 2005; Reardon et al, 2005) after
treatment with imatinib (400–1000mg daily) and HU (1000mg
daily). Each of these studies also confirmed that this combination
was well tolerated.
Enzyme-inducing anticonvulsant drugs (EIACDs; eg phenytoin,
carbamazepine, phosphenytoin, oxcarbamazepine, and pheno-
barbital) are known to accelerate the metabolism of imatinib,
resulting in a shorter plasma-elimination half-life (t1/2) and a lower
area under the plasma concentration time curve (AUC) (Reardon
et al, 2005; Wen et al, 2006). We sought to further evaluate the
efficacy and tolerability of imatinib in addition to HU among
patients with recurrent GBM treated on multi-institutional phase II
studies depending on the use of EIACDs or not. Specifically, for
study H2201, patients were not on EIACDs, whereas study H2202
only included patients on EIACDs. The primary end point was
objective overall response rate (ORR); secondary end points were
safety, overall survival (OS), and PFS.
PATIENTS AND METHODS
Study design and treatment
We conducted two, parallel open-label, multicentre, single-arm,
phase II trials. In study H2201, patients were not allowed to be on
EIACDs whereas patients were enrolled on study H2202 if they were
on EIACDs. The dose of imatinib differed between the trials to
account for the effect of EIACDs on imatinib metabolism (Reardon
et al, 2005; Wen et al, 2006): Patients enrolled on study H2201
received 600mg once a day, whereas those on study H2202 received
500mg twice a day. For both trials, patients received 500mg of HU
twice a day. The studies were identical in all other respects.
Medically appropriate efforts were used to maintain study-specific
EIACD exposure for patients on each study; however, H2201
patients were deemed off study if they initiated EIACDs and H2202
patients were similarly censored if they discontinued EIACDs.
Patients remained on study unless they withdrew consent,
developed tumour progression or unacceptable toxicity. During
the first year of treatment, patients were assessed every 4 weeks,
changing to every 8 weeks thereafter. The study was designed
according to respective national regulations and was approved by
local ethical review boards before patient accrual started. All
patients provided written informed consent according to local and
national regulations.
Patient eligibility
All patients were required to have institutional histological
confirmation of GBM that was at first recurrence after conven-
tional therapy and measurable disease on gadolinium-enhanced
MRI. After study entry, centralised review was conducted to
confirm histopathology. Satisfactory haematologic (haemoglobin
X10g per 100ml, absolute neutrophil count 41500 cells per litre,
platelets 4100000 cells per litre), biochemical (serum creatinine
o1.5mg per 100ml, BUN o25mg per 100ml; AST and bilirubin
o1.5 upper limit of normal) and performance status (ECOG
score p2 or Karnofsky X60%) parameters were also required.
Key exclusion criteria included peripheral oedema Xgrade 2;
pulmonary, pericardial or peritoneal effusions of any grade; an
excessive risk of an intracranial haemorrhage; major surgery
within 2 weeks before study entry; and concurrent warfarin
administration.
Patient assessments
Disease status was assessed using a modified version of the
Macdonald criteria (Macdonald et al, 1990), including an increase
in corticosteroid dosing, regardless of radiographic or clinical
assessment, as a criteria to define progressive disease (PD). Sites
performed each assessment, before submitting the data to a central
independent review (CIR) team. The CIR team included three
radiologists (two reviewers and an adjudicator) as well as a neuro-
oncologist who conducted a two-stage evaluation of each patient
assessment. First, steroid and MRI assessments were indepen-
dently determined and included in the database. Second, the site
neurologic assessment was incorporated to provide an overall
outcome assessment. Visits were assessed in sequence; older visits
could be reviewed, but newer visits could only be seen after
completion of the preceding visit. Adjudication occurred if the
overall visit conclusion differed between the two radiologists. To
minimise bias, all CIR team members were blinded to the patient
study identifier, the results of the other reader, and the final
outcome of the patient. Final outcome was hidden by presenting
data of each time point only after the previous time point had been
assessed.
Safety assessments included weekly complete blood counts and
monthly chemistry profiles. Treatment was held until any non-
haematologic grade 3 or 4 event resolved to grade p1, after which
the study regimen was resumed with a reduction in daily imatinib
dosing by 200mg. If the event recurred, HU was reduced to 500mg
a day. If the event recurred despite these dose modifications,
patients were taken off study. The above guidelines were also
followed for grade 3 or greater thrombocytopaenia and grade 4
neutropaenia. Myeloid and erythoid growth factors were permitted
according to established guidelines.
Tumour biomarker analysis
Archival tumour samples from either initial diagnosis or after
prior therapy failure were analysed at the Duke University Hospital
Cell Imaging Laboratory (Durham, NC, USA). Methylguanine
methyltransferase (MGMT), PDGFRa and PDGFRb, phospho-p44/
42 MAPK, phospho-S6 ribosomal protein, phospho-AKT, PTEN,
EGFR, and EGFRvIII were assessed using immunohistochemistry
(IHC) reagents and methods (Supplementary Methods). Similarly,
dual-colour fluorescent in situ hybridisation (FISH) was
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using commercially available probes, including EGFR/CEP 7,
PTEN/CEP 10 (Vysis, Downers Grove, IL, USA), and c-KIT/CEP
4 for EGFR, PTEN, and c-KIT DNA locus copy number
(Supplementary Methods). Genes were classified as polysomic or
amplified if their copy number relative to respective centromere
probe exceeded 1 or 2, respectively.
Pharmacokinetic analysis
Blood samples were collected from a subset of patients on each
study on days 6 and 29 before treatment and 0.5, 1, 2, 3, 4, 8, 12, 13,
14, and 24h after their morning dose. For these patients, HU was
initiated after the 24-h sample for day 6 was obtained. Plasma
supernatants were separated by centrifugation and immediately
frozen ( 201C). The day 29 plasma supernatants were split for
both imatinib and HU analyses. Plasma concentrations of imatinib
and its metabolite, CGP74588, were determined by high-pressure
liquid chromatography/mass spectrometry (Parise et al, 2003)
whereas HU plasma concentrations were measured by gas
chromatography and mass spectroscopy. The individual plasma
concentration of data for each subject was used to calculate
pharmacokinetic parameters according to the model-independent
approach using WinNonlin software (Version 5.2; Pharsight
Corporation, Mountain View, CA, USA). Nominal sampling times
were used for calculating summary statistics of the plasma
concentration data.
Statistical considerations
A total of 220 adult patients (110 in each study) were planned to
enroll. Wong et al (1999) previously reported a 5% radiographic
response rate among patients with GBM treated with TMZ at first
recurrence. In the current studies, 110 patients were estimated as
required per study to provide a 95%, two-sided confidence interval
for radiographic response to have a lower limit of 5%, including a
10% expected dropout rate.
An interim analysis was performed after 101 patients were
enrolled in both studies combined. Accrual continued until a data
cut-off occurred 4 months after the 101st patient had been enrolled
to allow for at least 16 weeks of treatment. At the interim analysis,
if there were p4 responses (CR or PR) observed from 101 patients,
both studies were to be terminated due to lack of efficacy. If the
studies continued, combination therapy was to be declared as
having insufficient activity if there were p15 responses observed
from the 220 patients to be recruited.
A log-rank test was used to compare the OS and PFS experience
of patient subgroups defined by various biomarkers. Patients with
inadequate samples to analyse for a particular marker were
excluded from that specific statistical analysis. Within subgroups,
the Kaplan–Meier estimator was used to generate estimates
of median OS and PFS, as well as 6-, 12-, and 24-month OS and
PFS rates.
RESULTS
Patient characteristics
The intent-to-treat (ITT) population consisted of 231 enrolled
patients including 131 on study H2201 and 100 on study H2202.
Study H2201 accrued more rapidly, hence a higher percentage of
eligible patients were not on EIACDs. Otherwise, characteristics of
patients accrued to both studies were comparable (Table 1).
Adequate tumour material for central histopathology review was
available from 177 patients (77.7%) and confirmed GBM in 158
cases (89.3%). This rate is comparable to that previously reported
in other multi-institutional studies (Stupp et al, 2005; Raymond
et al, 2008). The remaining patients had either grade 3 malignant
glioma (n¼11, 7.0%), grade 2 glioma (n¼2, 1.3%), or were non-
diagnostic (n¼6, 3.8%). Most patients (88.7%) had just one
measurable lesion at baseline. Only 11.7% of patients had
additional lesions documented for evaluation, which were too
small to measure (‘evaluable lesions’). According to the CIR,
9 patients (3.9%) had only evaluable lesions at their baseline MRI
scan. Thirty-three patients (14%) enrolled within 3 months of
XRT/daily TMZ completion; however, outcome among this subset
did not differ compared to the remaining patients (data not shown)
Table 1 Patient characteristics at enrolment (ITT population)
Study H2201 Study H2202 All patients
Variable Statistic/category N¼131 N¼100 N¼231
Age (years) Median 55.0 56.5 56.0
Range 18–80 21–75 18–80
Age group, n (%) 18–34 years 10 (7.6) 6 (6.0) 16 (6.9)
35–49 years 31 (23.7) 32 (32) 63 (27.3)
50–64 years 71 (54.2) 47 (47.0) 118 (51.1)
X65 years 19 (14.5) 15 (15.0) 34 (14.7)
Sex, n (%) Male 79 (60.3) 65 (65.0) 144 (62.3)
Female 52 (39.7) 35 (35.0) 87 (37.7)
Performance status
ECOG 0–1 107 (81.6) 86 (86.0) 193 (83.5)
ECOG 2 24 (18.3) 14 (14.0) 38 (16.5)
Time since initial diagnosis (months) Median 9.0 10.0 9.0
Range 3–45 2–63 3–63
Initial tumour histology, n (%)
a AA 6 (24.6) 6 (16.0) 12 (5.2)
GBM 124 (94.7) 94 (94.0) 218 (94.4)
Gliosarcoma 1 (0.8) 0 1 (0.4)
Time since last recurrence (days) Median 27.0 26.0 26.0
Range 1–165 0–222 0–222
Measurable lesions, n (%)
b,c 0 5 (6.8) 2 (7.1) 7 (6.9)
1 65 (89.0) 25 (89.3) 90 (89.1)
2 2 (2.7) 1 (3.6) 3 (3.0)
42 1 (1.4) 0 (0.0) 1 (1.0)
aAll patients must have independent histological confirmation of their diagnosis as part of their inclusion. This review is still ongoing at the time of the interim analysis.
bTumour
burden measurements are based on central independent review (CIR) data.
cTumour assessment information was assigned at baseline assessment (first MRI scan). All other data
were collected at screening (in some cases this equalled baseline).
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progression (Brandes et al, 2008; Brandsma et al, 2008) did not
influence the outcome of this study. No patients had to discontinue
study participation due to changing enzyme-inducing anti-
epileptic drug (EIAED) status.
Toxicity
The median times on study were 6 weeks (range, 1.3–91 weeks)
and 4 weeks (range, 0.1–102 weeks) for study H2201 and H2202,
respectively. A total of 195 patients (84.8%) received less than 180
days of therapy whereas 20 patients (8.7%) and 15 patients (6.5%)
remained on study for 180–365 days and 4365 days, respectively.
The adverse events seen in the study were as expected for this
population and these agents. In general, they were mild and
transient (Table 2). There were no major differences in adverse
events between the two studies. Dose adjustment or interruption
due to adverse events affected 34% of H2201 patients and 39%
of H2202 patients. Patients on each study (8%) discontinued
therapy due to toxicity. Among grade 3 or higher events, the most
common included fatigue (7.0%), neutropaenia (6.9%), and
thrombocytopaenia (6.9%). There were no grade 5 attributable to
adverse events.
Pharmacokinetic analyses
Population PK samples were obtained from 15 patients on study
H2201 and 6 patients on study H2202. Overall, imatinib,
CGP74588, and HU pharmacokinetic results were consistent with
those previously reported and confirm the marked impact of
EIAEDs on imatinib metabolism (Table 3; Reardon et al, 2005).
Specifically, dose-normalised Cmax and AUCs of imatinib were
lowered for patients on EIAEDs compared with those who were not
on EIAEDs. Slight elevations of CGP74588 compared with parent
drug ratio were noted for patients on EIAEDs (0.23 vs 0.19) or not
receiving EIAEDs (0.41 vs 0.35) in the presence of HU. Imatinib
exposure on day 29 (with HU) was slightly increased compared
with day 6 (imatinib alone) for patients on study H2201, but was
slightly decreased for patients on study H2202, although these
differences did not achieve statistical significance. The exposure
and elimination of HU were not different between patients
receiving or not receiving EIAEDs.
Tumour biomarker analysis
Table 4 summarises the number of patients who had sufficient
archival tumour material available for biomarker analysis by IHC
and FISH, as well as the association of marker expression with
outcome. Of note, 80 of 91 (88%) assessable tumours were positive
for PDGFRa, whereas 47 of 67 (70%) assessable tumours expressed
PDGFRb. Among 25 tumours that were assessable for c-KIT copy
number analysis by FISH, 1 (4%) had evidence of gene
amplification (Figure 1) and 1 (4%) was polysomic.
Outcome
Table 5 shows the study analysis populations. The safety
population was one less than the ITT population because one
patient was lost to follow-up immediately after baseline assess-
ments. At the time of data analysis, most patients were off study
with disease progression or death (82%), whereas adverse events,
withdrawal of consent, completion of planned therapy, and
miscellaneous factors accounted for 8, 5, 3, and 3% of study
discontinuations, respectively.
Overall, five patients on study H2201 (3.8%) and three on study
H2202 (3%) achieved either a PR or CR confirmed by the CIR
giving an ORR of 3.4% (Table 5). In addition, 19% of patients on
each study achieved stable disease (SD). Of note, 13 patients (5.6%)
were classified as CR or PR by local investigators, but were not
confirmed by the CIR. Nineteen patients (8.2%) had either a
confirmed CR or PR, or achieved SD lasting 6 months or more.
With one confirmed responder and three unconfirmed responders
at the interim analysis, a lack of efficacy for the drug combination
was concluded as per the statistical design, and the trial was closed
for accrual. However, accrual was sufficiently robust in the interval
between enrolment of the 101st patient and completion of the
interim analysis that study H2201 actually over-accrued, and study
H2202 accrued 100 of the planned 110 patients.
Progression-free survival rates at 6 months were 11.2% (95% CI,
5.7–16.6) for study H2201 and 9.9% (95% CI, 3.8-15.9) for study
H2202 (Table 5; Figure 2A). Progressive disease was defined by
MRI assessment in 114 patients (51.6%), whereas 41 patients
(18.6%) were defined as progressive by increased corticosteroid
use only and 26 patients (11.8%) solely by neurologic decline.
Forty patients (18.1%) died, without previous PD determination,
presumably due to PD. Median OS was 25.3 weeks (95% CI, 19.9–
33.0) for study H2201 and 27.1 weeks (95% CI, 19.9–39.1) for
study H2202 (Table 4; Figure 2B).
None of the tumour markers assessed by IHC among archival
tumour material obtained from patients correlated with PFS
(Table 4). However, single patients with either c-KIT amplification
or polysomy remained progression-free for 290 and 232 days,
Table 2 Adverse events in at least 10% of patients (Safety population)
Study H2201 Study H2202 All patients
N¼131 N¼99 N¼230
Adverse event n (%) n (%) n (%)
Nausea
Grade 3 0 2 (2.0) 2 (0.9)
Grade 4 0 0 0
All grades 50 (38.2) 39 (39.4) 89 (38.7)
Fatigue
Grade 3 7 (5.3) 6 (6.1) 13 (5.7)
Grade 4 3 (2.3) 0 3 (1.3)
All grades 41 (31.3) 37 (37.4) 78 (33.9)
Peripheral oedema
Grade 3 1 (0.8) 2 (2.0) 3 (1.3)
Grade 4 0 0 0
All grades 31 (23.7) 24 (24.2) 55 (23.9)
Diarrhoea
Grade 3 0 1 (1.0) 1 (0.4)
Grade 4 0 0 0
All grades 27 (20.6) 16 (16.2) 43 (18.7)
Thrombocytopaenia
Grade 3 8 (6.1) 2 (2.0) 10 (4.3)
Grade 4 4 (3.1) 2 (2.0) 6 (2.6)
All grades 23 (17.6) 11 (11.1) 34 (14.8)
Anaemia
Grade 3 5 (3.8) 0 5 (2.2)
Grade 4 0 0 0
All grades 21 (16.0) 11 (11.1) 32 (13.9)
Constipation
Grade 3 0 1 (1.0) 1 (0.4)
Grade 4 0 0 0
All grades 22 (16.8) 10 (10.1) 32 (13.9)
Rash
Grade 3 0 0 0
Grade 4 0 0 0
All grades 14 (10.7) 13 (13.1) 27 (11.7)
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srespectively. Compared with patients with normal c-KIT copy
number (n¼23), PFS was increased among those with either
c-KIT polysomy or amplification (P¼0.021).
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Table 4 Tumour marker analysis and progression-free survival
Variable Result
Number of
patients Median 95% CI P-value
Immunohistochemistry
MGMT Positive 25 37.0 28.0, 75.0 0.68
Negative 62 49.0 30.0, 55.0
EGFR Positive 52 50.0 29.0, 55.0 0.083
Negative 2 26.0 99.0, 43.0
EGFRvIII Positive 17 49.0 29.0, 57.0 0.863
Negative 73 50.0 30.0, 55.0
PTEN Positive 27 54.0 28.0, 62.0 0.88
Negative 54 39.0 30.0, 54.0
S6 Positive 13 54.0 28.0, 56.0 0.579
Negative 5 49.0 9.0, 57.0
MAPK Positive 27 31.0 29.0, 54.0 0.467
Negative 10 41.0 28.0,56.0
AKT Positive 24 43.0 29.0, 55.0 0.983
Negative 16 31.0 29.0, 57.0
VEGF Positive 39 39.0 29.0, 55.0 0.409
Negative 25 55.0 50.0, 83.0
PDGFRa Positive 80 49.0 31, 55.0 0.26
Negative 11 55.0 28.0, 232.0
PDGFRb Positive 47 55.0 37.0, 57.0 0.192
Negative 20 43.0 29.0, 55.0
Fluorescence in situ hybridisation
EGFR Increased 13 57.0 49.0, 112.0 0.802
Normal 19 54.0 29.0, 83.0
PTEN Deleted 7 54.0 29.0, 135.0 0.804
Normal 18 55.0 43.0, 83.0
c-KIT Increased 2 261.0 232.0, 290.0 0.021
Normal 23 54.0 43.0, 75.0
Abbreviations: MGMT¼methylguanine methyltransferase; PDGFR¼platelet-derived
growth factor receptor; VEGF¼vascular endothelial growth factor.
Figure 1 Representative example of c-KIT gene amplification detected
by fluorescence in situ hybridisation (FISH). High-level amplification of c-KIT
(red signals) detected along with two copies of chromosome 4
centromeres (green signals).
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sDISCUSSION
Two prior, single-institutional studies independently suggested that
the combination of imatinib and HU had anti-tumour activity
among patients with recurrent GBM. Dresemann (2005) first
reported that 6 of 30 patients (20%) achieved a radiographic
response whereas 11 additional patients (37%) achieved SD for a
median of 6 months (range 3–32 months). In a follow-up phase II
study among 33 patients, Reardon et al (2005) noted a radiographic
response rate of 9% and PFS-6 of 27%. The current phase II studies
Table 5 Patient outcome
Study H2201 Study H2202 All patients
N¼131 N¼100 N¼231
Analysis population n (%) n (%) n (%)
ITT population 131 (100) 100 (100) 231 (100)
Safety population 131 (100) 99 (99.0) 230 (99.6)
Per-protocol population 96 (73.3) 71 (71.0) 167 (72.3)
Disease evaluable population 105 (80.2) 80 (80.0) 185 (80.1)
Pharmacokinetic population 15 (11.5) 6 (6.0) 21 (91.0)
Disposition
Discontinued study treatment 131 (100) 100 (100) 231 (100)
Main cause of study treatment discontinuation
Disease progression 95 (72.5) 73 (73) 168 (72.7)
Death 11 (8.4) 10 (10.0) 21 (9.1)
Adverse event(s) 12 (9.2) 6 (6.0) 18 (7.8)
Subject withdrew consent 5 (3.8) 6 (6.0) 11 (4.8)
Completed prescribed treatment 4 (3.1) 3 (3.0) 7 (3.0)
Administrative problems 2 (1.5) 1 (1.0) 3 (1.3)
Protocol violation 2 (1.5) 0 2 (0.9)
Lost to follow-up 0 1 (1.0) 1 (0.4)
Best overall response, n (%)
CR 0 1 (1) 1 (0.4)
PR 5 (3.8) 2 (2.0) 7 (3.0)
SD 26 (19.8) 19 (19.0) 45 (19.5)
Lasting for more than 6 months 8 (6.1) 3 (3.0) 11 (4.8)
PD 79 (60.3) 63 (63.0) 142 (61.5)
Objective response (CR+PR), n (%) 5 (3.8) 3 (3.0) 8 (3.5)
95% confidence interval 1.3–8.7 0.6–8.5 1.5–6.7
Clinical benefit
a, n (%) 13 (9.9) 6 (6.0) 19 (8.2)
95% confidence interval 5.4–16.4 2.2–12.6 5.0–12.5
CR+PR+SD, n (%) 31 (23.7) 22 (22.0) 53 (22.9)
95% confidence interval 16.7–31.9 14.3–31.4 17.7–28.9
CR+PR, unconfirmed, n (%) 9 (6.9) 4 (4.0) 13 (5.6)
95% confidence interval 3.2–12.6 1.1–9.9 3.0–9.4
Progression-free survival time (weeks)
Median 6.1 4.6 5.6
95% confidence interval 4.1–7.9 4.1–7.9 4.1–7.9
Progression-free survival at 6 months (%)
Median 11.2 9.9 10.6
95% confidence interval 5.7–16.6 3.8–15.9 6.5–14.7
PD determination (%)
MRI assessment 61 (48.0) 53 (56.4) 46 (50.5)
Neurological examination but not by MRI 17 (13.4) 9 (9.6) 26 (11.8)
Increased steroid use only 23 (18.1) 18 (19.1) 41 (18.6)
Death without previous PD determination 26 (20.5) 14 (14.9) 40 (18.1)
Overall survival time (weeks)
Median 25.3 27.1 26.0
95% confidence interval 19.9–33.0 19.9–39.1 21.3–31.3
Abbreviations: CIR¼centralised independent review; CR¼complete response; ITT¼intent-to-treat; PD¼progressive disease; PR¼partial response; SD¼stable disease.
ITT population¼Patients who received at least one dose of any of the two study drugs (imatinib, HU). Safety population¼Patients from the ITT population who had at least
one post-baseline safety assessment. Disease evaluable population¼Patients in the ITT population without major protocol deviation. Per-protocol population¼Patients in the
ITT population with at least 25 days of treatment with either study drug, with a baseline MRI scan, with a post-baseline MRI scan or a record of death or progression, and without
major protocol deviation. Patients alive and without progression were considered as censored at time of last available tumour assessment. Progression-free survival time
percentiles and rates were calculated by Kaplan–Meier method.
aClinical benefit was defined as objective response or as SD lasting for 46 months from start of treatment.
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multi-institutional setting. If the current multi-institutional studies
achieved evidence of anti-tumour benefit comparable to that
observed in the two prior single-institutional studies, a randomised,
multicentre phase III study comparing imatinib in addition to HU to
alternative salvage therapy was anticipated.
H2201
Number at risk:
H2202
All patients
= censored
H2202 = censored
All patients = censored
Median time (95% CI)
H2201:      6.1 (4.1 – 7.9)
H2202:         4.6 (4.1 – 7.9)
All patients:  5.6 (4.3 – 7.7)
H2201
= censored
H2202 = censored
All patients = censored
Median time (95% CI)
H2201:      25.3 (19.9 – 33.0)
H2202:         27.1 (19.9 – 39.1)
All patients:  26.0 (21.3 – 31.3)
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H2201
Number at risk:
H2202
All patients
Progression-free survival time in weeks
0 112 104 96 88 80 72 64 56 48 40 32 24 16 8
231 195 156 118 95 81 70 60 42 38 25 3 9 49 12
100 1 5 7 11 12 16 25 30 33 41 50 63 86 5
131 109 0 4 7 18 27 30 33 35 40 48 54 68 93
Figure 2 Kaplan–Meier plots of progression-free survival (A) and overall survival (B) for patients enrolled on H2201 and H2202 studies.
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previously confirming that imatinib in addition to HU is well
tolerated among patients with recurrent GBM. The most common
toxicities were haematologic and included neutropaenia (grade 3,
n¼12, 5%; grade 4, n¼5, 1.7%) and thrombocytopaenia (grade 3,
n¼10, 4%; grade 4, n¼6, 3%). The most common non-
haematologic toxicities included nausea (39%), fatigue (34%),
peripheral oedema (24%), and diarrhoea (19%), although the
majority of these events were grade 2.
Outcome on the current studies was poorer than noted on the
prior single-institutional studies, and the trials were closed after
the interim analysis. Specifically, only 3.4% of patients achieved a
confirmed radiographic response, and the PFS-6 was only 10.6%.
Of note, we did not observe a significantly different outcome
among patients treated on the study H2201 and H2202 trials.
Several factors may have contributed to the discrepancy in
outcome between the current multicentre studies and the
previously reported single-institutional studies. First, single-centre
studies may bias towards enrolment of more favourable patients.
Approximately 28% of patients in the current studies received
less than 25 days of treatment, typically progressing or dying
within this 25-day period. Such patients probably had a poor
prognosis and rapid disease advancement on entry to the trial,
such that receipt of treatment may have been too late to control
disease. In contrast, none of the patients reported by Reardon et al
(2005) discontinued therapy prematurely due to rapidly
progressive tumour. Imatinib achieves plasma steady-state
concentrations after approximately 6 days, but additional time to
achieve stable concentrations within the brain is likely required
among patients with GBM due to the impact of the blood–brain
barrier.
Second, incorporation of rigorous independent, blinded,
centralised outcome review with strict assessment guidelines in
the current studies may have impacted the rates of determined
response (Dodd et al, 2008). In contrast, responses were assessed
solely by study investigators in the prior single-centre studies.
Third, this study included an increase in corticosteroid dosing,
independent of clinical status and radiologic findings, to define
PD. The Macdonald criteria define PD based on ‘X25% increase in
size of enhancing tumour or any new tumour on CT or MRI scans,
or neurologically worse, and steroids stable or increased.’ In fact,
the original publication stated, ‘Patients requiring escalating
steroid doses to maintain neurologic function, in the absence of
significant CT worsening (ie, o25% increase or no change) may
have early tumor progression but are included in stable category’.
Indeed, many clinicians do not interpret an increase in cortico-
steroids to be a sufficient ‘stand-alone’ criteria for defining PD
because clear-cut guidelines to specify when an increase in
corticosteroid dosing is appropriate for patients with primary
brain tumour are not defined, and no cut-off has been specified for
what change in dosage determines a meaningful ‘dose increase’.
Furthermore, corticosteroids are routinely prescribed to patients
with primary brain tumour to improve neurologic deterioration or
alleviate increased cerebral oedema due to several factors
independent of underlying tumour status, including overly
aggressive corticosteroid tapering, seizures, post-operative
sequellae, infection, metabolic disturbances, and vascular events.
In general, though the decision to increase corticosteroids is
individually made by the treating physician based on either
worsened neurologic symptoms or radiographic findings such as
increased oedema. Nonetheless, in the absence of co-morbid
events or changes due to concurrent medications, the need for
increased corticosteroids to treat neurologic deterioration is
usually due to progressive tumour. Moreover, increasing steroid
dosage may mask both clinical deterioration and increased
enhancement qualifying for progression. We therefore chose to
include this parameter in this study to increase the rigour of
PD assessment.
Biologic factors underlying response to imatinib are not well
characterised among patients with malignant glioma. In preclinical
GBM studies, PDGFR and CXCL12/SDF-1 expression are asso-
ciated with imatinib sensitivity (Hagerstrand et al, 2006). Although
expression of CXCL12/SDF-1 was not assessed in this study, IHC
expression of PDGFR did not correlate with PFS. However, we
noted statistically increased PFS among two patients with either
c-KIT gene amplification or polysomy compared with patients
with normal c-KIT copy number. Clearly, these results must be
interpreted cautiously due to the small number of patients.
However, to further investigate this potential association, we
evaluated c-KIT copy number among patients with available
archival tumour material who were treated on a previously
published phase 2 study (Reardon et al, 2005). Specifically, among
12 patients with adequate tumour material available for analysis,
3 had c-KIT polysomy or gene amplification. Although the
differences did not reach statistical significance (P¼0.15),
the median PFS and PFS-6 were 16.7 weeks (95% CI, 8.3–130.3)
and 40% (95% CI, 5.2–75.3%) for patients with increased c-KIT
copy number compared with 8.5 weeks (95% CI, 7.9–16.1) and
10% (95% CI, 0.6–35.8) for those with normal copy number.
Future studies to evaluate c-KIT gene copy number or protein
expression as a biomarker of response to imatinib therapy in
patients with recurrent GBM may be warranted.
Of note, Dresemann et al (2008) recently reported preliminary
results of a clinical trial in which patients with recurrent GBM were
randomised to receive either imatinib and HU vs HU alone. This
study noted an overall PFS-6 of 6% and no difference in median or
OS between the two study arms. This is the only study to date to
evaluate HU monotherapy for recurrent GBM and suggests that the
activity associated with the regimen of imatinib and HU may be
primarily related to HU.
Despite the previous single-institutional studies showing that
imatinib in addition to HU has modest anti-tumour benefit for
patients with recurrent GBM, this regimen had no significant
activity in this multi-institutional study that incorporated blinded
CIR. The decision to include an increase in corticosteroids as an
isolated criterion to define PD in this study remains controversial.
Finally, our observation that increased c-KIT copy number may be
associated with better outcome suggests that further investigation
of the potential prognostic and predictive value of c-KIT may be
warranted.
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